Partial
Not Aligned
Patient Risk:
Medium
Summary
Core drug identity, main indications, and cardiovascular risk-reduction/triglyceride-lowering claims align with the FDA label excerpts provided, but multiple non-label-supported claims about a Vascepa rebate and patient assistance eligibility/application/discount/documentation are included, which are not verifiable from the supplied prescribing information.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing icosapent ethyl.
Supported by label section 1 INDICATIONS AND USAGE (product identity context).
Vascepa is approved by the FDA to reduce triglyceride levels in adults with severe hypertriglyceridemia.
Supported by label section 1 INDICATIONS AND USAGE (adjunct to diet to reduce TG in adults with severe (≥500 mg/dL) hypertriglyceridemia).
Vascepa reduces the risk of cardiovascular events.
Supported by label sections 1 INDICATIONS AND USAGE and 14.1 Prevention of Cardiovascular Events (risk reduction of MI/stroke/revascularization/unstable angina; trial results show significant reduction in composite endpoints).
Vascepa was found in a randomized clinical trial (Journal of the American College of Cardiology, 2019) to reduce the risk of cardiovascular events.
Supported directionally by label section 14.1 Prevention of Cardiovascular Events (REDUCE-IT results show significant reduction in cardiovascular endpoints). Journal/year attribution is not shown in the supplied label excerpts, but the claimed outcome is supported.
Unsupported Statements
The Vascepa rebate program is designed to help patients who are struggling to afford Vascepa.
Not present in the supplied FDA prescribing information sections.
The Vascepa rebate program offers a significant discount on the cost of Vascepa for eligible patients.
Not present in the supplied FDA prescribing information sections.
To qualify for the Vascepa rebate, a patient must have a valid prescription for Vascepa.
Not present in the supplied FDA prescribing information sections.
To qualify for the Vascepa rebate, the patient must have insurance coverage that includes Vascepa as a covered medication.
Not present in the supplied FDA prescribing information sections.
To qualify for the Vascepa rebate, the patient must meet income requirements that vary by location and insurance coverage.
Not present in the supplied FDA prescribing information sections.
To qualify for the Vascepa rebate, a healthcare provider must determine Vascepa is medically necessary for the patient's treatment.
Not present in the supplied FDA prescribing information sections.
Patients can apply for the Vascepa rebate program through their insurance provider or the Vascepa website.
Not present in the supplied FDA prescribing information sections.
Patients may need to provide documentation such as proof of income or insurance coverage to support a rebate application.
Not present in the supplied FDA prescribing information sections.
A patient assistance program, such as the Vascepa Patient Assistance Program, can help cover the cost of Vascepa.
Not present in the supplied FDA prescribing information sections.
Patients can use a patient assistance program in conjunction with the Vascepa rebate program to maximize the rebate.
Not present in the supplied FDA prescribing information sections.
Contradictions
Important Omissions
Dosage and administration details for Vascepa (e.g., dosing regimen/administration instructions) were not provided in the AI claims, preventing verification against the label’s dosage/administration content.
Importance:
Moderate
No contraindications, boxed warnings, or other safety warnings/precautions content was included to evaluate alignment with those critical label elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Non-label-supported claims about rebate/patient assistance eligibility and application/documentation may mislead patients, while key safety-critical labeling elements were not provided for alignment assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Inclusion of multiple detailed rebate/patient assistance program claims that are absent from the supplied FDA prescribing information.
Suggested Improvement
Remove or clearly separate any rebate/patient assistance program details from FDA-label-alignment evaluation, and focus claims on FDA label-supported content (indications, trial-supported outcomes, and label-listed dosing and safety information).